AB Science: Maxim Group Initiates Coverage with a Target of 4 Euros
AB Science announced on December 18 that Maxim Group, an American investment banking services firm, has initiated coverage of its stock with a buy recommendation. The price target set by the analyst is 4.00 euros per share.
Mastering Mast Cell Inhibition
According to the press release, Maxim Group has published a study titled 'Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starting with ALS'. The analyst states that masitinib, AB Science's flagship molecule, has shown promising results in three neurodegenerative diseases, validating the company's mast cell inhibition approach. Maxim Group believes that the benefit-risk profile of masitinib is positive based on the observed efficacy data and tolerance profile. The study also mentions positive data in progressive multiple sclerosis and mild Alzheimer's disease, confirming the neuroprotective potential of the treatment according to the analyst. However, Maxim Group notes that it does not model these last two indications, considering them as additional opportunities.
Enhancing Existing Consensus
According to AB Science, this coverage by Maxim Group complements the existing consensus on the stock. The company indicates that three other analysts are already following the stock: Chardan, In Extenso Finance, and DNA Finance. The initiation of coverage by Maxim Group thus brings the number of financial analysts covering AB Science's stock to four. The company specifies that Maxim Group is an independent American company specializing in investment banking services, securities, and wealth management.
Focus on Kinase Inhibitors
Founded in 2001, AB Science focuses on the research, development, and marketing of protein kinase inhibitors, a class of targeted proteins that play a role in cellular signaling pathways. According to the press release, the company directs its programs towards diseases characterized by significant unmet medical needs, often fatal with short-term survival, rare, or refractory to existing treatments. Masitinib, the company's flagship compound, has already been registered in veterinary medicine and is under development in human medicine in the fields of oncology, neurological, inflammatory, and viral diseases. The company, headquartered in Paris, is listed on Euronext Paris.
